These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 17881746)
1. STAT3 signaling and the hyper-IgE syndrome. Levy DE; Loomis CA N Engl J Med; 2007 Oct; 357(16):1655-8. PubMed ID: 17881746 [No Abstract] [Full Text] [Related]
2. [STAT3 mutation identified in patients with Hyper-IgE syndrome]. Picard C Med Sci (Paris); 2008 Mar; 24(3):242-3. PubMed ID: 18334168 [No Abstract] [Full Text] [Related]
3. [Dominant negative STAT-3 mutations in hyper-IgE syndrome]. Dereure O Ann Dermatol Venereol; 2008 May; 135(5):432. PubMed ID: 18457738 [No Abstract] [Full Text] [Related]
4. A novel mutation in the linker domain of the signal transducer and activator of transcription 3 gene, p.Lys531Glu, in hyper-IgE syndrome. Kim HJ; Kim JH; Shin YK; Lee SI; Ahn KM J Allergy Clin Immunol; 2009 Apr; 123(4):956-8. PubMed ID: 19348930 [No Abstract] [Full Text] [Related]
5. Hyper IgE syndrome diagnosed in early infancy by gene analysis of STAT3 mutation. Watarai A; Niiyama S; Morita M; Bando Y; Minegishi Y; Katsuoka K Eur J Dermatol; 2011; 21(2):254-5. PubMed ID: 21454152 [No Abstract] [Full Text] [Related]
6. STAT3 mutation in the original patient with Job's syndrome. Renner ED; Torgerson TR; Rylaarsdam S; Añover-Sombke S; Golob K; LaFlam T; Zhu Q; Ochs HD N Engl J Med; 2007 Oct; 357(16):1667-8. PubMed ID: 17942886 [No Abstract] [Full Text] [Related]
7. A novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene, in hyper-IgE syndrome. Papanastasiou AD; Mantagos S; Papanastasiou DA; Zarkadis IK Mol Immunol; 2010 Apr; 47(7-8):1629-34. PubMed ID: 20149460 [TBL] [Abstract][Full Text] [Related]
8. Identification of a novel STAT3 mutation in a patient with hyper-IgE syndrome. Mogensen TH; Jakobsen MA; Larsen CS Scand J Infect Dis; 2013 Mar; 45(3):235-8. PubMed ID: 22992060 [TBL] [Abstract][Full Text] [Related]
10. Challenges of genetic counseling in patients with autosomal dominant diseases, such as the hyper-IgE syndrome (STAT3-HIES). Spielberger BD; Woellner C; Dueckers G; Sawalle-Belohradsky J; Hagl B; Anslinger K; Bayer B; Siepermann K; Niehues T; Grimbacher B; Belohradsky BH; Renner ED J Allergy Clin Immunol; 2012 Dec; 130(6):1426-8. PubMed ID: 22981789 [No Abstract] [Full Text] [Related]
11. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Jiao H; Tóth B; Erdos M; Fransson I; Rákóczi E; Balogh I; Magyarics Z; Dérfalvi B; Csorba G; Szaflarska A; Megarbane A; Akatcherian C; Dbaibo G; Rajnavölgyi E; Hammarström L; Kere J; Lefranc G; Maródi L Mol Immunol; 2008 Nov; 46(1):202-6. PubMed ID: 18706697 [TBL] [Abstract][Full Text] [Related]
12. STAT3: an important regulator of multiple cytokine functions. Stepkowski SM; Chen W; Ross JA; Nagy ZS; Kirken RA Transplantation; 2008 May; 85(10):1372-7. PubMed ID: 18497672 [TBL] [Abstract][Full Text] [Related]
13. Hyperimmunoglobulin E syndrome with a novel STAT3 mutation. Anolik R; Elmariah S; Lehrhoff S; Votava HJ; Martiniuk FT; Levis W Dermatol Online J; 2009 Aug; 15(8):16. PubMed ID: 19891924 [TBL] [Abstract][Full Text] [Related]
14. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. Minegishi Y; Karasuyama H Int Immunol; 2009 Feb; 21(2):105-12. PubMed ID: 19088064 [TBL] [Abstract][Full Text] [Related]
15. Hyper IgE (Job's) syndrome: a primary immune deficiency with oral manifestations. Freeman AF; Domingo DL; Holland SM Oral Dis; 2009 Jan; 15(1):2-7. PubMed ID: 19036057 [TBL] [Abstract][Full Text] [Related]